Small-molecule direct antithrombins: Argatroban

Best Practice and Research: Clinical Haematology

Volumn 17, Issue 1, 2004, Pages 127-138

  Fareed, Jawed ^a   Jeske, Walter P ^b  

^a Dept of Pathology and Pharmacology ^*  (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anticoagulant; Antithrombin agent; Antithrombotic; Peptidomimetic

Indexed keywords

ALTEPLASE; ANTITHROMBIN; ARGATROBAN; CYTOKINE; FIBRINOGEN; HEPARIN; HEPARIN DERIVATIVE; HIRUDIN; HIRUDIN DERIVATIVE; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NEUTRALIZING ANTIBODY; NITRIC OXIDE; PLASMIN; RECOMBINANT HIRUDIN; SERINE PROTEINASE; STREPTOKINASE; THROMBIN; TICLOPIDINE; UROKINASE; XIMELAGATRAN;

ACUTE HEART INFARCTION; AGE; ANTICOAGULATION; ARTERY THROMBOSIS; BIOASSAY; BLEEDING DISORDER; BLOOD CLOT LYSIS; BLOOD CLOTTING TIME; BLOOD FLOW; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIOPULMONARY BYPASS; CELL STIMULATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DOWN REGULATION; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG USE; ENDOTHELIUM CELL; ENZYME INHIBITION; EXTRACORPOREAL CIRCULATION; GENDER; HEART ATRIUM FIBRILLATION; HUMAN; IN VITRO STUDY; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MICROANGIOPATHY; MOLECULAR WEIGHT; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTION; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOGENESIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS; VALIDATION PROCESS; VASCULARIZATION; VENOUS THROMBOEMBOLISM;

EID: 2942665487     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.03.008     Document Type: Review

References (61)

1. Callas D & Fareed J. Comparative pharmacology of site directed antithrombin agents. Implication in drug development. Thrombosis and Haemostosis 1995; 74: 473-481.
2. Callas DID, Hoppensteadt D & Fareed J. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly-developed site-directed thrombin inhibitory drugs. Seminars in Thrombosis and Hemostasis 1995; 21: 177-183.
3. Fenton JW. Regulation of thrombin generation and functions. Seminars in Thrombosis and Hemostasis 1988; 14: 234-240.
4. Lunven C, Gauffeny C, Lecoffre C, et al. Inhibition by argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thrombosis and Hemostasis 1996; 22: 233-241.
5. Bush LR. Argatroban, a selective, potent thrombin inhibitor. Cardiovascular Drug Reviews 1991; 9: 247-263.
6. Banner DW & Hadvary R Crystallographic analysis at 3.0 A resolution of the binding to human thrombin and four active site-directed inhibitors. The Journal of Biological Chemistry 1991; 266: 20085-20093.
7. Kikumoto R, Tamoa Y, Tezuka T et al. Selective inhibition of thrombin by (2R, 4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl) sulfonyl]-L-arginyl)]-2-piperidinecarboxylic acid. Biochemistry 1984; 23: 85-90.
8. Nagasawa H, Fukutake K, Hada M, et al. Antithrombin effect of a new synthetic thrombin inhibitor, MD 805, on blood coagulation. Biomedical Sciences 1981; 2: 1-8.
9. Tobu M, Iqbal O, Messmore HL, et al. Influence of different anticoagulant agents on fibrinopeptide a generation. Clinical and Applied Thrombosis and Hemostasis 2003; 9: 273-292.
10. Berry CN, Girardot C, Lecoffre C, et al. Effects of the sythetic thrombin inhibitor argatroban on fibrin-or-clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thrombosis and Haemostasis 1994; 72: 381-386.
11. Niwa C, Niwa M, Maeda M, et al. Effects of newly synthesized antithrombin agent (MD-805) on blood coagulation system. Saishin Igaku 1985; 40: 2677-2683.
12. Tamao Y, Yamamoto T, Hirata T, et al. Effect of argatroban on blood coagulation. Japanese Journal of Pharmaceutical Therapy 1986; 14: 7-12.
13. Verstraete M. Direct thrombin inhibitors: appraisal of the antithrombotic/hemorrhagic balance. Thrombosis and Haemostasis 1997; 78: 1366-1371.
14. Fareed J, Hoppensteadt D, Iqbal 0, et al. Practical issues in the development of argatroban: a perspective. Pathophysiology of Haemostasis and Thrombosis 2002; 32(supplement 3): 56-65.
15. Weitz JI & Crowther MA. New anticoagulants; current status and future potential. American Journal of Cardiovascular Drugs 2003; 3: 201-209.
16. Jeske W, Walenga JM, Lewis BE, et al. Pharmacology of argatroban. Expert Opinion in Investigative Drugs 1999; 8: 625-654.
17. Hursting MJ, Becker JC, Lewis BE, et al. Differential effects of argatroban and heparin on Hemochron and Hemo-tec activated clotting times in patients undergoing coronary interventional procedures. Journal of the American College of Cardiology 1997; 29: 500a.
18. Berry CN, Girardot C, Lecoffre C, et al. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thrombosis and Haemostasis 1994; 72: 381-386.
19. Lunven C, Gauffeny C, Lecoffre C, et al. Inhibition by argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-asociated thrombin. Thrombosis and Haemostasis 1996; 75: 154-160.
20. Verstraete M. Modulating platelet function with selective thrombin inhibitors. Haemostasis 1996; 26(supplement 4): 70-77.
21. Czervionke RL, Hoak JC, Haycraft DL, et al. Inhibition of thrombin-induced platelet adherance to vascular cells by synthetic thrombin inhibitor no 805. Transactions of the Association of American Physicists 1983; 96: 271-277.
22. Kosugi T, Nakamura M, Saitoh S, et al. Changes of rabbit platelet function following simultaneous administration of ticlopidine hydrochloride and argipidone (MD-805). International Journal of Tissue Reactions 1992; 14: 141-148.
23. Eidt JF, Allison P, Noble S, et al. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. The Journal of Clinical Investigation 1988; 101: 125-136.
24. Nakamura K, Hatano Y & Mori K. Thrombin-induced vasoconstriction in isolated cerebral arteries and the influence of a synthetic thrombin inhibitor. Thrombosis Research 1985; 40: 715-720.
25. Maruyama I. Therapeutic evaluation of recombinant thrombomodulin. Nippon Rinsho 1992; 50: 2561-2567.
26. Berry CN, Girard D & Lochot S. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time. British Journal of Pharmacology 1994; 113: 1209-1214.
27. Callas DD, Iqbal O, Hoppensteadt D, et al. Fibrinolytic compromise by synthetic and recombinant thrombin inhibitors: implications in the treatment of thrombotic disorders. Clinical and Applied Thrombosis and Hemostasis 1995; 1: 114-124.
28. Valji K, Arun K & Bookstein JJ. Use of a direct thrombin inhibitor (argatroban) during pulse-spray thrombolysis in experimental animals. Journal of Vascular and Interventional Radiology 1995; 6: 91-95.
29. Eisert WG, Koch V, Rigter B, et al. Prevention of rethrombosis after thrombolysis by synthetic thrombin inhibitor argipidine (MID 805). Thrombosis and Haemostasis 1989; 62: 329-333.
30. Tomodo H. Experimental evaluation of coronary thrombodynamics and effects of pharmacological interventions in acute coronary syndromes. Japanese Circulation Journal 1992; 56: 1184-1190.
31. Hara H, Tamao Y, Kikumoto R, et al. Effect of a synthetic thrombin inhibitor MCI-9038 on experimental models of disseminated intravascular coagulation in rabbits. Thrombosis and Haemostasis 1987; 37: 165-170.
32. Maekawa I. Clinical evaluation of synthetic thrombin inhibitor MD-805 in disseminated intravascular coagulation (DIC). Therapeutic Research 1987; 6: 409-417.
33. Morishita K, Wada M, Kumada T, et al. Effect of ticlopidine and other antithrombotics on the venous thrombosis induced by endothelial damage of jugular vein in rats. Thrombosis Research 1991; 63: 373-384.
34. Matsukura H, Uzawa S, Takeda H, et al. Experimental extracorporeal circulation with a synthetic thrombin inhibitor, MD-805, without heparin. Journal of Japanese Association for Thoracic Surgery 1983; 31: 1377-1382.
35. Swan SK & Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20: 318-329.
36. Higuchi A, Hirano T, Ishizaka T, et al. Clinical report on the treatment of antithrombin MD-805. Therapeutic Research 1987; 6: 865-871.
37. Higuchi M, Nakajima T, Kakishita E, et al. Therapeutical effect of MD-805, a synthetic antithrombin drug, on disseminated intravascular coagulation. Medical Consultant for New Drugs 1986; 23: 2347-2353.
38. Higuchi M, Kunitomi 0, Nishida Y, et al. Effect of MD-805, a synthetic thrombin inhibitor, on disseminated intravascular coagulation development on hematologic disorders. Japanese Journal of Clinical Hematology 1985; 26: 1754-1762.
39. Kumon K, Tanaka K, Nakajima N, et al. Experiences of treatment of DIC with thrombin inhibitor MD-805 after cardiovascular surgery. Progress in Medicine Japan) 1987; 7: 353-359.
40. Kumon K, Tanaka K, Sugahara K, et al. The effect of synthetic thrombin inhibitor MD-805 on DIC before and after cardiovascular surgery. Diagnostic and Treatment 1983; 71: 2208-2212.
41. Maekawa I, et al. Clinical evaluation of synthetic thrombin inhibitor MD-805 in disseminated intravascular coagulation (DIC). Therapeutic Research 1987; 6: 409-417.
42. Niikura H. Experience of using MD-805 in one case with DIC complicated with pneumonia. Haemostasis 1992; 37: 35-40.
43. Sugishima T, Matsuo N, et al. Studies on effects of MD-805 of DIC. Journal of the New Remedial Clinic 1987; 36: 171-182.
44. Yamada H & Jap J. Beneficial use of argatroban in DIC. Clinical Hematology 1982; 23: 811-817.
45. Kario K, Kodama K, Koide M, et al. Thrombin inhibition in the acute phase of ischaemic stroke using argatroban. Blood Coagulation & Fibrinolysis 1995; 6: 423-427.
46. Kitani M, Kobayashi S, Yamaguchi S, et al. The effect of an antithrombin agent, MD 805, which acts selectively on progressive cerebral thrombosis: comparison with that of urokinase therapy. Clinical Research 1986; 63: 251-258.
47. Tazaki Y, Kobayashi S, Togi H, et al. Clinical effects of the antithrombin drug, MD 805, on acute cerebral thrombosis-clinical study in early phase II. Japanese Pharmaceutical Therapy (Kiso to Rinsho) 1986; 20: 9041-9048.
48. Kawada T, Mieda T, Abe H, et al. Left heart bypass with the bio-medicus centrifugal pump by the use of an antithrombin agent, argatroban. Kyobu Geka 1994; 47: 803-808.
49. Vermeer F, Vahanian A, Fels PW, et al. Intravenous argatroban versus heparin as co-medication to alteplase in the treatment of acute myocardial infarction; preliminary results of the ARGAMI pilot study. Journal of the American College of Cardiology 1997; 29: 185A.
50. Suzuki S, Sakamoto S, Adachi K, et al. Effect of argatroban on thrombus formation during acute coronary occlusion after balloon angioplasty. Thrombosis Research 1995; 77: 369-373.
51. Nagasawa H, Fukutake K, Hada M, et al. Phase one study of synthetic antithrombin agent (MD-805). Single and multiple administration studies. Japanese Journal of Pharmaceutical Therapy 1981; 12: 359-375.
52. Izawa O, Katsuki M, Komatsu T, et al. Pharmacokinetics studies of argatroban (MD-805) in human-concentrations of argatroban and its metabolites in plasma, urine and feces during and after drip intravenous infusion. Japanese Journal of Pharmaceutical Therapy 1986; 14(supplement 5): 251-262.
53. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838-1843.
54. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Archives of Internal Medicine 2003; 163: 1849-1856.
55. Lewis BE, Matthai Jr. WH, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin induced thrombocytopenia. Catheterization and Cardiovascular Interventions 2002; 57: 177-184.
56. Kieta DR, McCammon AT, Holman WL, et al. Hemostatic analysis of a patient undergoing off-pump coronary artery bypass surgery with argatroban anticoagulation. Anesthesia and Analgesia 2003; 96: 956-958.
57. Edwards JT Hamby JK & Worrall NK. Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. The Annals of Thoracic Surgery 2003; 75: 1622-1624.
58. Ohno H, Higashidate M & Yokosuka T Argatroban as an alternative anticoagulant for patients with heparin allergy during coronary artery bypass. Heart and Vessels 2003; 18: 40-42.
59. Green JA, Cooper CL, Falcucci CA, et al. Argatroban for off-pump coronary artery bypass surgery. Anesthesia and Analgesia 2003; 97: 1201.
60. Behar S, Hod H & Kaplinsky E. Argatroban versus heparin as adjuvant therapy for thrombolysis for acute myocardial infarction: safety considerations ARGAMI-1 study. Circulation 1998; 98(supplement I): 453-454.
61. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular weight heparin. Sixth ACCP consensus conference on antithrombotic therapy. Chest 2001; 119(supplement): 64S-94S.